Patents by Inventor John E. Burnes
John E. Burnes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7474920Abstract: A device and method to detect slow ventricular tachycardia, deliver anti-tachycardia pacing therapies, and delay a scheduled shock therapy if the ventricular tachycardia is not terminated or accelerated. Preferably, a shock therapy is delayed after verifying hemodynamic stability based on a hemodynamic sensor. After a shock is delayed, the device operates in a high alert mode for redetecting an accelerated tachycardia. Anti-tachycardia pacing therapies are repeated during the shock delay. A number of conditions can trigger delivery of the delayed shock therapy including a specified period of elapsed time; determination that the patient is likely to be asleep; detection of myocardial ischemia; detection of compromised hemodynamics, or detection of a substantially prone position or sudden change in position.Type: GrantFiled: December 12, 2005Date of Patent: January 6, 2009Assignee: Medtronic, Inc.Inventors: John E. Burnes, Paul J. Degroot
-
Publication number: 20080269823Abstract: Automated adjustment of a pre-excitation interval (PEI) used to deliver hemodynamically efficient fusion pacing therapy.Type: ApplicationFiled: April 30, 2007Publication date: October 30, 2008Inventors: John E. Burnes, Thomas J. Mullen, Aleksandra T. Sambelashvili
-
Patent number: 7289850Abstract: In some embodiments, a method of applying stimulation pulse therapy to excitable tissue may include one or more of the following steps: (a) delivering a PESP stimulation therapy to the excitable tissue for a cardiac cycle, (b) delivering a NES stimulation therapy to the excitable tissue during certain cardiac cycles, (c) determining physiologic demand of the patient based on at least one physiologic measurement, (d) determining physiologic demand being placed on a heart based on at least one physiologic measurement, and ceasing the delivery of the NES and PESP stimulation therapy when physiologic demand returns to a base level, and (e) determining physiologic demand being placed on a heart based on at least one physiologic measurement, and modulating the ratio of the number of cardiac cycles in which the NES stimulation therapy is delivered to the number of cardiac cycles in which the PESP stimulation therapy is delivered based on physiologic demand.Type: GrantFiled: April 28, 2005Date of Patent: October 30, 2007Assignee: Medtronics, Inc.Inventors: John E. Burnes, Lawrence J. Mulligan, Randall L. Knoll
-
Patent number: 7248918Abstract: An implantable medical device (IMD) provides an alert to a patient that has the IMD implanted in their body. The alert is used to remind the patient to schedule and/or proceed to a follow-up physician visit. The reminder is also used to remind the patient to initiate a remote communication so that stored data or other information may be transmitted to a remote computer network or other communication node.Type: GrantFiled: April 25, 2003Date of Patent: July 24, 2007Assignee: Medtronic, Inc.Inventors: John E. Burnes, Luc R. Mongeon
-
Patent number: 7228174Abstract: Methods and devices for determining optimal Atrial to Ventricular (AV) pacing intervals and Ventricular to Ventricular (VV) delay intervals in order to optimize cardiac output. Impedance, preferably sub-threshold impedance, is measured across the heart at selected cardiac cycle times as a measure of chamber expansion or contraction. One embodiment measures impedance over a long AV interval to obtain the minimum impedance, indicative of maximum ventricular expansion, in order to set the AV interval. Another embodiment measures impedance change over a cycle and varies the AV pace interval in a binary search to converge on the AV interval causing maximum impedance change indicative of maximum ventricular output. Another method varies the right ventricle to left ventricle (VV) interval to converge on an impedance maximum indicative of minimum cardiac volume at end systole. Another embodiment varies the VV interval to maximize impedance change.Type: GrantFiled: April 29, 2002Date of Patent: June 5, 2007Assignee: Medtronics, Inc.Inventors: John E. Burnes, Yong K. Cho, David Igel, Luc R. Mongeon, John C. Rueter, Harry Stone, Jodi Zilinski
-
Patent number: 7181284Abstract: The bi-ventricular implantable pulse generator described and depicted herein enables hemodynamic efficiencies for patients suffering from intraventricular conduction delays or conduction blockage. The pulse generator effectively overcomes such conduction delay or block (e.g., left bundle branch block, “LBBB,” or right bundle branch block, “RBBB”) by delivering a novel form of cardiac resynchronization therapy (CRT). Specifically, a single ventricular pre-excitation pacing stimulus is triggered from an atrial event (e.g., intrinsic or evoked depolarization). The triggering event may emanate from the right atrium (RA) or the left atrium (LA). A single ventricular pre-excitation pacing stimulus is delivered prior to the intrinsic depolarization of the other ventricle and thus promotes intraventricular electromechanical synchrony during CRT delivery.Type: GrantFiled: March 17, 2004Date of Patent: February 20, 2007Assignee: Medtronic, Inc.Inventors: John E. Burnes, Thomas J. Mullen
-
Patent number: 7155278Abstract: Neurostimulation is delivered to one or more predetermined locations on or within a patient in order to treat effects of sleep apnea by modulating autonomic nervous activity. Delivery of neurostimulation at predetermined locations can decrease sympathetic nervous activity and/or increase parasympathetic nervous activity, countering the increased intrinsic sympathetic activity associated with apnea-arousal cycles. In some embodiments, neurostimulation is delivered to the spinal cord of the patient via an implanted electrode. In other embodiments, neurostimulation is delivered transcutaneously to the spinal cord or other locations via electrodes located on the surface of the patient. In some embodiments, delivery of neurostimulation is initiated or modified in response to detection of apneas.Type: GrantFiled: April 21, 2003Date of Patent: December 26, 2006Assignee: Medtronic, Inc.Inventors: Gary W. King, Marcus J. Mianulli, Michael R. S. Hill, Thomas J. Mullen, Roy L. Testerman, John E. Burnes, Xiaohong Zhou
-
Patent number: 7130684Abstract: Methods and devices for improving ventricular contractile status of a patient suitably exploit changes in ventricular pressure and/or dP/dtmax to provide and/or optimize a response to a patient. The ventricular pressure may be appropriately correlated to intracellular calcium regulation, which is indicative of contractile status. To assess ventricular contractile status, the device suitably observes a cardiac perturbation of the patient and measures force interval potentiation following the perturbation. The contractile potentiation can then be stored and/or quantified in the implantable medical device to determine the ventricular contractile status of the patient, and an appropriate response may be provided to the patient as a function of the ventricular contractile status. Examples of responses may include administration of drug or neuro therapies, modification of a pacing rate, or the like.Type: GrantFiled: April 30, 2003Date of Patent: October 31, 2006Assignee: Medtronic, Inc.Inventors: Lawrence J. Mulligan, Michael R. S. Hill, John E. Burnes
-
Patent number: 7107093Abstract: A system and method for monitoring electrical dispersion of the heart is provided including an implantable medical device and associated electrode system for sensing cardiac signals from a combination of two or more local and/or global EGM sensing vectors and/or subcutaneous ECG sensing vectors. Activation and recovery times and the activation-recovery intervals are measured from a selected cardiac cycle for each sensing vector. Dispersion is determined as the differences between activation times, recovery times and/or ARIs measured from each of the sensing vectors. An increase in dispersion indicates a worsening of heart failure and/or an increased risk of arrhythmias. Accordingly, a cardiac therapy may be delivered or adjusted in response to a detected increase in dispersion.Type: GrantFiled: April 29, 2003Date of Patent: September 12, 2006Assignee: Medtronic, Inc.Inventor: John E. Burnes
-
Patent number: 7079887Abstract: A hemodynamic status of a patient is determined in an implanted medical device (IMD) by observing a perturbation of the patient's heart, measuring heart rate turbulence resulting from the perturbation, and quantifying the heart rate turbulence to determine the hemodynamic status. The perturbation may be naturally-occurring, or may be generated by the implantable medical device. The patient's response to heart rate turbulence may also be used to provide a response to the patient, such as providing an alarm and/or administering a therapy. Heart rate turbulence may also be used to tune and/or optimize a device parameter such as A-V or V—V pacing intervals.Type: GrantFiled: March 20, 2003Date of Patent: July 18, 2006Assignee: Medtronic, Inc.Inventors: John E. Burnes, Lawrence J. Mulligan, Michael R. S. Hill
-
Patent number: 7027871Abstract: An implantable device is described that collects and aggregates data from non-implanted medical devices external from a body of a patient. The device may also collect and aggregate data from medical devices implanted within the body. The implantable device includes a wireless transceiver to acquire physiological data from the external medical devices, and a storage medium to store the physiological data. A processor retrieves the physiological data and communicates the physiological data to a remote patient management system. The device may collect the physiologic data from the various external data sources, possibly over an extended period of time, and stores the data for subsequent upload to a common patient management system. In addition, the implantable device may collect physiological data from other medical devices implanted within the patient. In this manner, the device provides a central point for collection and aggregation of physiological data relating to the patient.Type: GrantFiled: October 31, 2002Date of Patent: April 11, 2006Assignee: Medtronic, Inc.Inventors: John E. Burnes, Luc R. Mongeon
-
Patent number: 7010344Abstract: A device and method to detect slow ventricular tachycardia, deliver anti-tachycardia pacing therapies, and delay a scheduled shock therapy if the ventricular tachycardia is not terminated or accelerated. Preferably, a shock therapy is delayed after verifying hemodynamic stability based on a hemodynamic sensor. After a shock is delayed, the device operates in a high alert mode for redetecting an accelerated tachycardia. Anti-tachycardia pacing therapies are repeated during the shock delay. A number of conditions can trigger delivery of the delayed shock therapy including a specified period of elapsed time; determination that the patient is likely to be asleep; detection of myocardial ischemia; detection of compromised hemodynamics, or detection of a substantially prone position or sudden change in position.Type: GrantFiled: April 26, 2002Date of Patent: March 7, 2006Assignee: Medtronic, Inc.Inventors: John E. Burnes, Paul J. DeGroot
-
Patent number: 6931272Abstract: In general, the invention is directed to monitoring fluid retention that may accompany congestive heart failure and pulmonary edema. A medical device, such as an implanted pacemaker or an external defibrillator, senses electrical signals associated with the periodic depolarization and re-polarization of a heart. The device processes the electrical signals to obtain one or more “cardiac parameters,” which reflect pulmonary edema. By monitoring the cardiac parameters, the device monitors pulmonary edema. Cardiac parameters comprise the amplitude of the QRS complex, the integral of the QRS complex, or the integral of the QRST segment and the like. When the device detects fluid buildup, the device may respond by taking remedial action and/or generating an alert.Type: GrantFiled: April 29, 2003Date of Patent: August 16, 2005Assignee: Medtronic, Inc.Inventor: John E. Burnes
-
Publication number: 20040220632Abstract: In general, the invention is directed to monitoring fluid retention that may accompany congestive heart failure and pulmonary edema. A medical device, such as an implanted pacemaker or an external defibrillator, senses electrical signals associated with the periodic depolarization and re-polarization of a heart. The device processes the electrical signals to obtain one or more “cardiac parameters,” which reflect pulmonary edema. By monitoring the cardiac parameters, the device monitors pulmonary edema. Cardiac parameters comprise the amplitude of the QRS complex, the integral of the QRS complex, or the integral of the QRST segment and the like. When the device detects fluid buildup, the device may respond by taking remedial action and/or generating an alert.Type: ApplicationFiled: April 29, 2003Publication date: November 4, 2004Applicant: Medtronic, Inc.Inventor: John E. Burnes
-
Publication number: 20040220636Abstract: Accordingly, according to the present invention a programmable IMD provides a patient with an essentially customized cardiac pacing therapy resulting in enhanced hemodynamic function. In particular, the present invention provides for refined tuning of pacing parameters to cause the heart to pump blood and perfuse in an efficient manner. In general, the invention promotes good hemodynamic operation through programming of an implantable medical device (IMD) as a function of one or more hemodynamic data sensed by a device located external to the body of the patient relying on said data as gathered either by discrete internal measuring device or an external device. The ability to share data among and between an IMD, an IMD programming device and a hemodynamic monitoring or measuring device spaced from the IMD (i.e., either an implantable device or external to the patient) allows for improved selection of pacing parameters to optimize hemodynamic function.Type: ApplicationFiled: April 29, 2003Publication date: November 4, 2004Applicant: Medtronic, Inc.Inventor: John E. Burnes
-
Publication number: 20040220635Abstract: A system and method for monitoring electrical dispersion of the heart is provided including an implantable medical device and associated electrode system for sensing cardiac signals from a combination of two or more local and/or global EGM sensing vectors and/or subcutaneous ECG sensing vectors. Activation and recovery times and the activation-recovery intervals are measured from a selected cardiac cycle for each sensing vector. Dispersion is determined as the differences between activation times, recovery times and/or ARIs measured from each of the sensing vectors. An increase in dispersion indicates a worsening of heart failure and/or an increased risk of arrhythmias. Accordingly, a cardiac therapy may be delivered or adjusted in response to a detected increase in dispersion.Type: ApplicationFiled: April 29, 2003Publication date: November 4, 2004Applicant: Medtronic, Inc.Inventor: John E. Burnes
-
Publication number: 20040220640Abstract: A system and method are provided for controlling extra systolic intervals during extra systolic stimulation delivered to effectively produce post-extra systolic potentiation (PESP) to improve hemodynamic function for the treatment of cardiac mechanical insufficiency. Controlling the interval is based on measurements of the electrical restitution properties of myocardial tissue. A parameter related to the action potential duration is measured from an electrical signal received from the heart during extra systolic stimulation at different intervals. An electrical restitution condition is determined from the measured action potential duration related parameter. An operating interval is set based on the measured electrical restitution. Methods for controlling the interval further include setting the operating ESI based on electrical restitution and/or the mechanical effect of PESP on post-extra systoles.Type: ApplicationFiled: April 29, 2003Publication date: November 4, 2004Applicant: Medtronic, Inc.Inventors: John E. Burnes, Vincent E. Splett
-
Publication number: 20040220639Abstract: Methods and devices for improving ventricular contractile status of a patient suitably exploit changes in ventricular pressure and/or dP/dtmax to provide and/or optimize a response to a patient. The ventricular pressure may be appropriately correlated to intracellular calcium regulation, which is indicative of contractile status. To assess ventricular contractile status, the device suitably observes a cardiac perturbation of the patient and measures force interval potentiation following the perturbation. The contractile potentiation can then be stored and/or quantified in the implantable medical device to determine the ventricular contractile status of the patient, and an appropriate response may be provided to the patient as a function of the ventricular contractile status. Examples of responses may include administration of drug or neuro therapies, modification of a pacing rate, or the like.Type: ApplicationFiled: April 30, 2003Publication date: November 4, 2004Applicant: Medtronic, Inc.Inventors: Lawrence J. Mulligan, Michael R.S. Hill, John E. Burnes
-
Publication number: 20040220631Abstract: An implantable system and method are provided for detecting myocardial electrical recovery time and for controlling the delivery of cardiac stimulation pulses relative to the detected recovery time. One or more fiducial points on a T-wave signal sensed from one or more intracardiac EGM or subcutaneous ECG signals are detected for estimating myocardial recovery time. Extra systolic stimulation pulses are delivered at an extra systolic interval based on a detected recovery time to effectively produce post-extra systolic potentiation while preventing delivery of extra systolic stimuli during the vulnerable period.Type: ApplicationFiled: April 29, 2003Publication date: November 4, 2004Applicant: Medtronic, Inc.Inventors: John E. Burnes, Nirav Vijay Sheth, Chris Zillmer, Vincent E. splett
-
Publication number: 20040215269Abstract: An implantable medical device (IMD) provides an alert to a patient that has the IMD implanted in their body. The alert is used to remind the patient to schedule and/or proceed to a follow-up physician visit. The reminder is also used to remind the patient to initiate a remote communication so that stored data or other information may be transmitted to a remote computer network or other communication node.Type: ApplicationFiled: April 25, 2003Publication date: October 28, 2004Applicant: Medtronic, Inc.Inventors: John E. Burnes, Luc R. Mongeon